|
|
||||||||
Technical Briefs |
1 Departamento de Ginecologia e Obstetrícia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil;2 Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil;3 Centro de Cirurgia de Epilepsia, Hospital de Clínicas, Departamento de Neurologia, Psiquiatria e Psicologia Médica, Universidade de São Paulo, SP, Brazil
aaddress correspondence to this author at: Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, Avenida Ramiro Barcelos, 2600-Anexo, CEP 90035-003, Porto Alegre, RS, Brazil; fax 55-51-33165540 or 55-51-33165535, e-mail roska@ufrgs.br
| The first 300 words of the full text of this article appear below. |
Eclampsia is defined as the occurrence of seizures and/or coma resulting from hypertensive encephalopathy on a background of preeclampsia (1). Eclampsia appears to be caused by a failure of the brains autoregulatory response to increases in blood pressure, leading to an increase in cerebral perfusion pressure with overperfusion injury similar to that observed in hypertensive encephalopathy (2)(3). Brain edema and hemorrhage ensue, as observed in imaging studies (4)(5), and there is evidence to suggest that these alterations can cause ischemia to brain cells. These events lead to neurologic symptoms (6), including seizures as well as cortical blindness, aphasia, limb weakness, psychosis, coma, and cerebrovascular accidents. Studies have analyzed various diagnostic methods, such as transcranial Doppler measurements, as a way to evaluate neurologic involvement in preeclampsia (3)(7). To date, however, there is no reliable laboratory marker to identify patients at risk for eclampsia or its related complications.
S100B is a 21-kDa protein physiologically produced and released primarily by astrocytes in the central nervous system (CNS), where it exerts neurotrophic and gliotrophic actions (8). Because
95% of S100B is located in the CNS, the results of several studies have suggested that an increase in S100B in blood and cerebrospinal fluid could be a potential marker of neural injury, indicating reactive gliosis, astrocytic death, and/or bloodbrain barrier dysfunction. Accordingly, increased S100B concentrations in cerebrospinal fluid and/or blood have been reported in several pathologic conditions causing acute and chronic brain injury, such as head trauma (9), stroke (10), schizophrenia (11), and human T-lymphotropic virus type 1-associated myelopathy (12).
Some studies have also evaluated S100B as a marker of recent seizures. Although S100B has been shown to be increased
The following articles in journals at HighWire Press have cited this article:
![]() |
D. Gazzolo, E. Marinoni, R. Di Iorio, M. Lituania, M. Marras, M. Bruschettini, P. Bruschettini, R. Frulio, F. Michetti, F. Petraglia, et al. High Maternal Blood S100B Concentrations in Pregnancies Complicated by Intrauterine Growth Restriction and Intraventricular Hemorrhage Clin. Chem., May 1, 2006; 52(5): 819 - 826. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |